Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
British Journal of Cancer|September 5, 2019
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cellsNicholas R Jette, Suraj Radhamani, Greydon Arthur, et al.
Cancer Medicine|March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitorsMichael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.
Plos One|June 18, 2026
Effectiveness and implementation of a primary healthcare intervention for multimorbidity and frailty among urban older adults in India: Protocol for the Multi-FrAME cluster randomized trialJaya Singh Kshatri, Haimanti Bhattacharya, Siddhartha Goutam, et al.
JAMA Network Open|December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination ImmunotherapyAlexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.
JTO Clinical and Research Reports|April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint InhibitorsDaniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.
The Oncologist|April 3, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint InhibitorsIgor Stukalin, Vishal Navani, Mehul Gupta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
Pageof 2